{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:20:58Z","timestamp":1791116458006,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.vaccine.2006.03.048","type":"journal-article","created":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T12:13:31Z","timestamp":1143893611000},"page":"5064-5072","source":"Crossref","is-referenced-by-count":25,"title":["Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques"],"prefix":"10.1016","volume":"24","author":[{"given":"V. Ra\u00fal","family":"G\u00f3mez-Rom\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"George J.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal K.","family":"Potti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Demberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Gravlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Treece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranajit","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Gregory","family":"Alvord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip D.","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Robert-Guroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.03.048_bib1","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1128\/JVI.71.11.8531-8541.1997","article-title":"An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge","volume":"71","author":"Buge","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib2","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1128\/JVI.73.9.7430-7440.1999","article-title":"Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251","volume":"73","author":"Buge","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib3","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1016\/S0264-410X(03)00266-4","article-title":"Boosting of SIV-specific cellular immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv\/rev and SIVgag recombinants","volume":"21","author":"Zhao","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.048_bib4","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.4049\/jimmunol.170.8.4281","article-title":"A replication competent Ad5hr-SIV recombinant priming\/subunit boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity in Mamu-A*01 rhesus macaques","volume":"170","author":"Malkevitch","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib5","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1128\/JVI.77.16.8607-8620.2003","article-title":"Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env\/rev, gag, and\/or nef vaccines and boosted with SIV gp120","volume":"77","author":"Patterson","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/vim.2005.18.236","article-title":"Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following Ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE","volume":"18","author":"Pinczewski","year":"2005","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.4049\/jimmunol.174.4.2185","article-title":"Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251","volume":"174","author":"G\u00f3mez-Rom\u00e1n","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib8","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1128\/JVI.77.15.8354-8365.2003","article-title":"Improved protection of rhesus macaques against intrarectal SIVmac251 challenge by a replication competent Ad5hr-SIVenv\/rev and Ad5hr-SIVgag recombinant priming\/gp120 boosting regimen","volume":"77","author":"Zhao","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib9","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/JVI.78.5.2212-2221.2004","article-title":"Protection against mucosal simian immunodeficiency virus SIVmac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting","volume":"78","author":"Patterson","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/aid.1993.9.395","article-title":"Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees","volume":"9","author":"Natuk","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2006.03.048_bib11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1089\/aid.1994.10.1443","article-title":"Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration","volume":"10","author":"Lubeck","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2006.03.048_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nm0697-651","article-title":"Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization","volume":"3","author":"Lubeck","year":"1997","journal-title":"Nature Med"},{"key":"10.1016\/j.vaccine.2006.03.048_bib13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/JVI.72.2.1052-1059.1998","article-title":"Induction of neutralizing antibodies in chimpanzees to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime\/boost vaccine regimen in chimpanzees","volume":"72","author":"Zolla-Pazner","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib14","doi-asserted-by":"crossref","first-page":"10275","DOI":"10.1128\/JVI.72.12.10275-10280.1998","article-title":"Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus","volume":"72","author":"Robert-Guroff","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib15","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J Virol"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2006.03.048_bib16","first-page":"89","article-title":"A call for replicating vector prime\/protein boost strategies in HIV vaccine design","author":"Malkevitch","year":"2004","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2006.03.048_bib17","series-title":"Vaccines","first-page":"492","article-title":"Adenovirus vaccines","author":"Rubin","year":"1988"},{"key":"10.1016\/j.vaccine.2006.03.048_bib18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/milmed\/160.6.300","article-title":"Adenovirus vaccines in the U.S. military","volume":"160","author":"Gaydos","year":"1995","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2006.03.048_bib19","first-page":"2149","volume":"vol. 2","author":"Horwitz","year":"1996"},{"key":"10.1016\/j.vaccine.2006.03.048_bib20","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1073\/pnas.86.10.3823","article-title":"Role of early region 3 (E3) in pathogenesis of denovirus disease","volume":"86","author":"Ginsberg","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.03.048_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/viro.2001.1248","article-title":"Insertion of HIV-1 genes into Ad4\u0394E3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion","volume":"292","author":"Patterson","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.03.048_bib22","first-page":"350","article-title":"Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses","volume":"71","author":"Berencsi","year":"1994","journal-title":"Lab Invest"},{"key":"10.1016\/j.vaccine.2006.03.048_bib23","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.gt.3301527","article-title":"Development of formulations that enhance physical stability of viral vectors for gene therapy","volume":"8","author":"Croyle","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2006.03.048_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0264-410X(91)90033-3","article-title":"Evaluation of adenovirus type 4 and 7 recombinant hepatitis B vaccines in dogs","volume":"9","author":"Chengalvala","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.048_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-0934(99)00184-6","article-title":"Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology","volume":"86","author":"Romano","year":"2000","journal-title":"J Virol Meth"},{"key":"10.1016\/j.vaccine.2006.03.048_bib26","series-title":"SAS system for mixed models","author":"Littell","year":"1996"},{"key":"10.1016\/j.vaccine.2006.03.048_bib27","volume":"vol. 1","author":"Milliken","year":"1992"},{"key":"10.1016\/j.vaccine.2006.03.048_bib28","series-title":"Mixed-effects models in S and S-plus","author":"Pinheiro","year":"2000"},{"key":"10.1016\/j.vaccine.2006.03.048_bib29","series-title":"New generation vaccines","first-page":"393","article-title":"Mucosal immunization and needle-free infection devices","author":"Levine","year":"2004"},{"key":"10.1016\/j.vaccine.2006.03.048_bib30","first-page":"695","article-title":"Oral immunization against poliomyelitis","volume":"23","author":"Payne","year":"1960","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2006.03.048_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2105\/AJPH.50.7.1013","article-title":"Problems associated with the use of live poliovirus vaccine","volume":"50","author":"Melnick","year":"1960","journal-title":"Am J Public Health"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2006.03.048_bib32","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine","volume":"17","author":"Levine","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.048_bib33","first-page":"237","article-title":"Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction safety, immunogenicity, excretion and non-target effects","volume":"84","author":"Cryz","year":"1995","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2006.03.048_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jama.1966.03100060085025","article-title":"Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers","volume":"195","author":"Chanock","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2006.03.048_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.1966.03100060093026","article-title":"Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. Specific protective effect against epidemic disease","volume":"195","author":"Edmondson","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2006.03.048_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a120744","article-title":"Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection","volume":"86","author":"Gutekunst","year":"1967","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/infdis\/119.1.60","article-title":"Communicability of enteric live adenovirus type 4 vaccine in families","volume":"119","author":"Mueller","year":"1969","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.03.048_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/infdis\/119.1.51","article-title":"Spread of enteric live adenovirus type 4 vaccine in married couples","volume":"119","author":"Stanley","year":"1969","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.03.048_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/infdis\/140.1.48","article-title":"Simultaneous administration of live, enteric-coated adenovirus types 4, 7, and 21 vaccines: safety and immunogenicity","volume":"140","author":"Takafuji","year":"1979","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.03.048_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/infdis\/124.2.148","article-title":"Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans","volume":"124","author":"Top","year":"1971","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.03.048_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/infdis\/122.4.239","article-title":"Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses","volume":"122","author":"Smith","year":"1970","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.03.048_bib42","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.169.9.4778","article-title":"Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses","volume":"169","author":"Hel","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.03.048_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/viro.2002.1722","article-title":"Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques","volume":"304","author":"Hel","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.03.048_bib44","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/80481","article-title":"Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques","volume":"6","author":"Hel","year":"2000","journal-title":"Nature Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06003549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06003549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T13:30:16Z","timestamp":1586784616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06003549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":44,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0264410X06003549"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.03.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}